Contact

ALS Worldwide welcomes any questions or comments you might have.  We provide free, personalized and confidential support services to anyone in the ALS community—whether you are a patient or a loved one, friend, health care professional or caregiver of someone diagnosed.

Get help now! Fill out the Online Profile Form or if you would prefer to talk with someone by email or phone first, please contact us at [email protected] or 1-608-663-0920.

For all other inquiries, please use the email form to the right and we will respond promptly to your request.Thank you.

ALS Worldwide
5808 Dawley Drive
Fitchburg, WI 53711‑7209

ALS Worldwide
June 14, 2015

On The Horizon

Keep up with groundbreaking developments and new discoveries in research for ALS/MND. The following links contain information about clinical trial efforts and medication approvals being pursued and other subjects important on our collective horizon. 

1. Skin cells may provide a new diagnostic tissue for ALS/MND. Tissue-engineered skin may eventually allow a better search for biomarkers, test diagnostic methods and monitor effectiveness of potential treatments. although more research is needed.

2. Eisai Pharmaceuticals applies for new drug application for Methylcobalamin as ALS/MND treatment. ALS Worldwide is pleased that its six-year history with high dosage injectable methylcobalamin and Eisai's extensive Phase 2/3 clinical trials in Japan at University of Tokushima will now achieve international new drug status for methylcobalamin.

3. Q-Therapeutics will begin new stem cell clinical trials after FDA approval of IND. Q-Therapeutics will hopefully soon join Neuralstem and Brainstorm as the only FDA-approved active stem cell clinical trials in the US and elsewhere.

4. Is diabetes an ALS Link? No one knows for sure. While a Danish study suggests linkage, this may, in the end, lead nowhere.  Still, the examination of seemingly incongruent factors may provide a deeper understanding of ALS/MND . 

5. Link between Immune system and ALS/MND  confirmed at University of Montreal. An important analysis both because of its use of C. elegans worms (an important, inexpensive, rapid analysis ALS animal model) and the key factor of inflammation, an immune response indicator, in the development of ALS/MND. This supports several other lines of evidence identifying altered immune function as a participant in ALS pathogenesis and/or progression.